NVAX
Novavax
October 9, 2026 · intraday
- Rarity
- 2.18
- Peak move
- +18.26%
- Float cap
- $1.7B
Novavax is a Gaithersburg, Maryland-based vaccine company that develops recombinant protein-based nanoparticle vaccines and its proprietary Matrix-M adjuvant. It sells its protein-based, non-mRNA COVID-19 vaccine, Nuvaxovid, to governments and health systems, and licenses its technology to partners such as Sanofi, Takeda and the Serum Institute of India, which uses Matrix-M in its malaria vaccine. Its pipeline spans seasonal influenza, COVID-influenza combinations, RSV and other infectious-disease candidates.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
8 events · 0 from SEC or newswire · 0 timed with the moveregulatory_approvalSanofi's Phase 3 trial of a COVID-influenza combination vaccine using Novavax's Nuvaxovid received national regulatory approvals in Belgium, Germany and Portugal, with enrollment to begin in November and triggering a $125 million milestone payment from Sanofi to Novavax.
public_healthWHO Director-General Tedros Adhanom Ghebreyesus said on October 7 that a full risk assessment was not possible because the cause of the Irkutsk lab worker's death is undetermined, and Dr. Maria Van Kerkhove said WHO had asked Russia's health ministry for test results and contact details.
public_healthWHO spokesperson Christian Lindmeier said tests on contacts of a 28-year-old researcher who died of pneumonia at Russia's Irkutsk Anti-Plague Research Institute found no plague bacteria or dangerous pathogens, with epidemic risk assessed as medium-to-low for Irkutsk, low for Russia and very low for Europe.
analyst_ratingBofA analyst Alec Stranahan raised his price target on Novavax (NVAX) to $8 from $7 while keeping an Underperform rating, as part of a Q3 earnings preview for the biotech sector.
peer_disclosureCiti said recent swings in vaccine stocks including Novavax and Moderna illustrated their sensitivity to health-related headlines, with the suspected Russian plague case unconfirmed and contacts testing negative, and said it favours immunology, oncology, cardiometabolic and rare-disease names.
borrow_cost_spikeNovavax short interest stood at 30.43% of float, about 49.9 million shares as of mid-September, requiring roughly 10 trading days of average volume to cover, and Monday's volume equaled about 40% of the short position, fueling a squeeze.
clinical_readoutVaxcyte reported positive topline results from the pivotal Phase 3 OPUS-1 trial of its 31-valent pneumococcal conjugate vaccine VAX-31, meeting all prespecified primary immunogenicity and safety endpoints versus Pfizer's Prevnar 20 and Merck's Capvaxive in adults 50 and older, with Vaxcyte shares rising about 50%.
regulatory_approvalNovavax partners Sanofi and Takeda received approvals for an XFG-adapted formulation of Nuvaxovid in the US, EU and Japan for the 2026-2027 vaccination season, with US clearance covering ages 65+ and ages 12-64 with a high-risk condition.